ArticleOpen life sciences2026
Effects of red palm oil intervention on serum lipids, hepatic antioxidant capacity and gut microbiota in high-fat diet-fed mice.
Article in Open life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-fat diets (HFDs) can induce oxidative stress and gut microbiota imbalance, highlighting the need to explore functional dietary lipids such as red palm oil (RPO) for metabolic health improvement. This study investigated the effects of RPO intervention administered through oral gavage on growth performance, serum lipid profile, hepatic antioxidant capacity, and gut microbiota in HFD-fed mice. Compared to the high-fat control (HO) group, RPO treatment significantly reduced triglycerides (TG) and total cholesterol (TC), and increased high-density lipoprotein cholesterol (HDL-C). Furthermore, hepatic antioxidant capacity was markedly enhanced, as evidenced by improved superoxide dismutase (SOD) and catalase (CAT) activities and decreased malondialdehyde (MDA) levels in the HFD group receiving RPO. Moreover, RPO supplementation reduced serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST), and attenuated hepatic steatosis. Gut microbiota analysis showed that RPO administration enhanced the relative abundance of beneficial bacteria while reducing potentially harmful taxa. Overall, these findings demonstrate that oral gavage of RPO can effectively alleviate HFD-induced metabolic disturbances by improving lipid metabolism, enhancing hepatic antioxidant defenses, and modulating gut microbial composition.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.